2,767 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Quent Long Short Global Small Cap Fund LP

Key Points

• Quent Long Short Global Small Cap Fund bought a new stake of 2,767 shares in Thermo Fisher Scientific (NYSE:TMO) in Q4, valued at about $1.603 million, and institutional investors now own roughly 89.23% of the stock.
• Q1 results beat expectations — $11.01B revenue and $5.44 adjusted EPS — but softer underlying organic growth and mixed FY2026 guidance pressured the stock despite broad analyst bullishness and a consensus target of $631.25.
• CEO Marc N. Casper sold 5,000 shares (≈$2.56M) and EVP Gianluca Pettiti sold 400 shares, while Thermo Fisher raised its quarterly dividend to $0.47 (annualized $1.88).

Quent Long Short Global Small Cap Fund LP bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,767 shares of the medical research company's stock, valued at approximately $1,603,000.

Other hedge funds have also added to or reduced their stakes in the company. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $29,000. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the third quarter worth $28,000. Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific in the third quarter worth $31,000. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its stake in Thermo Fisher Scientific by 195.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 68 shares of the medical research company's stock worth $39,000 after purchasing an additional 45 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares of the company's stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is owned by corporate insiders.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat consensus on both revenue ($11.01B) and adjusted EPS ($5.44), showing resilience in lab products and biopharma services. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Positive Sentiment: Several analysts reaffirm Buy ratings and call the pullback overdone; TD Cowen reiterated Buy (PT cut) and other firms maintained bullish views citing long-term catalysts (AI in labs, reshoring). Thermo Fisher Scientific: Stock Pullback Seen as Overdone Amid Solid Fundamentals and Second-Half Growth Drivers
• Neutral Sentiment: The company nudged up its FY 2026 outlook overall, but the guidance band showed mixed signals (EPS and revenue targets near or slightly below Street expectations), leaving room for investor disappointment. Thermo Fisher Raises 2026 Outlook Despite First-Quarter Organic Revenue Growth Miss
• Negative Sentiment: Underlying organic growth was softer than investors hoped and management highlighted mixed segment performance (softness in analytical instruments and specialty diagnostics), which pressured sentiment despite the beat. Thermo Fisher falls after earnings top estimates, but growth concerns persist
• Negative Sentiment: Guidance nuances: the EPS range (24.640–25.120) is essentially in line with consensus but slightly uneven vs. expectations, contributing to profit-taking. TMO Q1 Earnings & Revenues Top Estimates, Stock Down in Pre-Market
• Negative Sentiment: Broader market and sector pressure (tech-led sell-off and softer healthcare-group trading) plus geopolitical-driven “modest inflation” risk flagged by management amplified the pullback. Thermo Fisher Flags 'Modest Inflation' Risk Amid Middle East Tensions Equities Fall Intraday Amid Tech Sell-Off; Oil Rises

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Stifel Nicolaus boosted their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a research report on Friday, January 9th. Citigroup boosted their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a research report on Friday, January 30th. TD Cowen lowered their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research report on Friday, January 30th. Evercore reiterated an "outperform" rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, Barclays lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research note on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $631.25.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $466.93 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The company has a market cap of $173.52 billion, a PE ratio of 26.32, a P/E/G ratio of 2.66 and a beta of 0.97. The business has a 50 day moving average of $499.83 and a 200 day moving average of $549.98. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.68 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 10.60%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.